CIVB vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CIVB presents a conflicting profile: a weak Piotroski F-Score of 3/9 indicates deteriorating operational health, yet the company maintains a strong track record of earnings beats and an attractive valuation. Trading at a Price-to-Book of 0.91 and well below its Graham Number of $39.0, the stock is fundamentally undervalued from a defensive standpoint. However, the discrepancy between strong revenue growth (15.3%) and flat YoY earnings growth (-1.4%), combined with the low health score, suggests internal inefficiencies. The outlook is neutral as the valuation cushion battles operational weakness.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CIVB vs JPM: Head-to-Head Comparison
This page compares Civista Bancshares, Inc. (CIVB) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.